We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Antibacterial Resistance Revealed in Women with UTIs

By LabMedica International staff writers
Posted on 08 Sep 2017
Nearly 20% of women aged 15-29 are diagnosed with a urinary tract infection (UTI) and antibiotic resistance prolongs UTI treatment and resistance profiles vary regionally. More...
This regional variation is an important consideration in guiding empirical treatment selection.

Regional studies in the USA have identified tetracycline resistance in over a third of Ureaplasma spp. isolates, but no studies have evaluated antibiotic resistance levels in college-aged women with first-time UTI, which has been estimated at USD 3.5 billion in USA costs.

Scientists at the University of Florida (Gainesville, FL, USA) tested a panel of antibiotics and determined the minimum inhibitory concentrations (MICs) of Ureaplasma spp. and 10 Mycoplasma hominis isolates obtained from urine of college-aged women with first-time UTI. The study included 180 women with symptomatic first-time UTIs, along with 80 age-matched controls and 35 of the women had recurrent UTIs.

The investigators reported that low antibiotic resistance was found in this population of women with first-time UTI. Two U. parvum isolates were resistant: one to levofloxacin (MIC: 4 μg/mL) and one to tetracycline (MIC: 8 μg/mL). All M. hominis and U. urealyticum isolates were sensitive. For the Ureaplasma spp., MIC90s were highest against gentamicin (21 μg/mL) and lowest against doxycycline (0.25 μg/mL). When comparing MIC levels between Ureaplasma spp., U. urealyticum had significantly higher MICs against each antibiotic except doxycycline.

For resistant isolates, the genetic mechanisms of resistance were determined. Polymerase chain reaction (PCR) amplification identified tetM present in the tetracycline resistant isolate, and a S83W mutation within the parC gene of the quinolone resistant isolate. Mary B. Brown, PhD, a Professor in the Department of Infectious Diseases and Immunology, said, “To our knowledge, this is the first report of this specific genetic mutation in Ureaplasma in the USA, and only the third report anywhere in the world. Antibiotics like penicillin and the other β-lactamases that interfere with cell wall synthesis are totally useless against the Mollicutes.” The study was published on August 21, 2017, in the journal Antimicrobial Agents and Chemotherapy.

Related Links:
University of Florida


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.